A randomized, double-blind, placebo-controlled clinical trial was performed on 24 patients between 30 and 60 to investigate the effects of UA (150 mg) on metabolic syndrome, insulin sensitivity and inflammation [146]. The gene discussed is INS; the disease is metabolic syndrome.